The product is an oncology support drug that prevents chronic cumulative cardiotoxicity caused by high dose anthracycline
Totect is an emergency oncology intervention, which is indicated to reverse the toxic effects of anthracycline
chemotherapy in case of extravasation.
Annamycin is an anthracycline
intended for the treatment of relapsed or refractory AML.
National Institute for Health and Clinical Excellence (NICE) as a treatment for patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens for advanced disease (prior therapy may have included an anthracycline
or a taxane, and capecitabine) in NICE's Final Appraisal Determination (FAD).
The team also found that dexrazoxane has proven helpful in preventing many of the cardiotoxic effects of anthracycline
treatment, without reducing its anticancer effects.
In order to provide optimal treatment to this subpopulation of cancer patients with hypertension comorbidity, it is necessary to understand the potential effects of hypertension and anthracycline
treatment on short- and long-term cardiac function.
Due to their broad antineoplastic activity, anthracycline
are the most widely used agents in oncological practice.
The exact mechanism of anthracycline
related cardiomyopathy is poorly understood a commonly accepted theory involves myocardial damage caused by mitochondrial injury and free radical formation2.
Past clinical trials in younger, healthier women showed improved survival, but also increased heart complications linked to trastuzumab, especially when combined with a frequently used therapy called anthracycline
Reviewing literature we find that several risk factors have been mentioned for cardiotoxicity of anthracyclines
; these risk factors include: the cumulative anthracycline
dose, length of post-therapy interval, rate of anthracycline
administration, individual anthracycline
dose, type of anthracycline
, concomitant radiation therapy, concomitant other chemotherapy agents, pre-existing cardiac risk factors, comorbidities, age, sex, and genetic factors [5-12].
The study also found that a regimen without the thug Adriamycin, an anthracycline
commonly used to treat breast cancer but one that, especially when paired with Herceptin, can cause permanent heart damage, was comparable to a regimen with Adriamycin.
Cardiomyopathy which develops with combined use of radiotherapy and anthracycline
group medications is one of these problems.